(c)自2024年3月8日起至本公告日期(包括该日)，董事会成员及董事委员会的组成概无变更;截至本公告日期，董事会由六名成员组成，即：裘东方先生及张生海先生，各为执行董事;崔光球先生，为非执行董事;邓敏仪女士、易八贤先生及王喆先生，各为独立非执行董事。Boillhealthcare (01246) announced that, in response to the allegations made on July 22, 2024 regarding the company, it is hereby stated that...
Futubull Financial News APP reported that Boillhealthcare (01246) announced that on July 22, 2024, regarding the announcement of changes in the company's directors and related updates of the director list, roles and functions...
(b) The aforementioned announcement was issued by the former company secretary without proper authorization from the board of directors. The Company reserves the right to take appropriate legal action against the former company secretary. Shareholders and investors of the Company should refer to the information in this announcement and the director list, roles and functions announced by the Company on March 8, 2024...
(c) From March 8, 2024 to the date of this announcement (inclusive), there has been no change in the composition of the members of the board of directors or the director committees. As of the date of this announcement, there are six members of the board of directors, namely: Mr. Qiu Dongfang and Mr. Zhang Shenghai, both as executive directors; Mr. Cui Guangqiu, as non-executive director; Ms. Deng Minyi, Mr. Yi Baxian and Mr. Wang Zhe, all as independent non-executive directors.
The board of directors has decided to dismiss Mr. Yuan Weiqiang from his position as company secretary and Mr. Yuan will no longer be the authorized representative of the Company as required by Rule 3.05 of the Listing Rules, or the Company's legal process agent for service of legal process or notices under Section 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from July 23, 2024.
Mr. Zhang Shenghai, as an executive director, has been appointed as the authorized representative and legal process agent with effect from July 23, 2024.